NCT02181985View on ClinicalTrials.gov

Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)

PHASE3CompletedINTERVENTIONAL
Enrollment

5,989

Participants

Timeline

Start Date

May 31, 2000

Primary Completion Date

April 30, 2001

Conditions
Myocardial Infarction
Interventions
DRUG

Full dose TNK-tPA

DRUG

Half dose TNK-tPA

DRUG

Heparin

DRUG

Enoxaparin

DRUG

Abciximab

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02181985 - Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI) | Biotech Hunter | Biotech Hunter